{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:07:58Z","timestamp":1790899678272,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jconrel.2023.07.027","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T06:34:31Z","timestamp":1690439671000},"page":"913-927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks"],"prefix":"10.1016","volume":"360","author":[{"given":"Amirah E.-E.","family":"Aly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey Findlay","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandi E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghyun","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.E.","family":"Baddeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo L.","family":"Casal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza S.M.","family":"Rahavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale D.O.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.07.027_bb0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0015","series-title":"Behav. Neurobiol. Huntingt. Dis","first-page":"33","article-title":"The neuropathology of Huntington\u2019s disease","author":"Waldvogel","year":"2015"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0020","series-title":"Neurobiol. Huntingt. Dis. Appl. Drug Discov.","article-title":"Huntington\u2019s disease: Clinical features and routes to therapy","author":"Paulson","year":"2011"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0030","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0035","doi-asserted-by":"crossref","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0040","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0045","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0050","first-page":"awac458","article-title":"AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington\u2019s disease mouse model","author":"Thomson","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0055","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","article-title":"AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models","volume":"13","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0060","first-page":"36","article-title":"Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease","volume":"48","author":"Caron","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0065","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0075","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0080","author":"Ionis Pharmaceuticals, Inc."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0085","author":"Ionis Pharmaceuticals, Inc"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0090","author":"Biogen"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0095","author":"Hoffmann-La Roche"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0100","author":"Roche"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bjae.2019.11.002","article-title":"Complications associated with intrathecal drug delivery systems","volume":"20","author":"Delhaas","year":"2020","journal-title":"BJA Educ."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105652","article-title":"Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice","volume":"166","author":"Caron","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0115","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in Huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","article-title":"Antisense oligonucleotide therapy: from design to the Huntington disease clinic","volume":"36","author":"Rook","year":"2022","journal-title":"BioDrugs."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.30802\/AALAS-CM-17-000096","article-title":"Hydrocephalus after intrathecal Administration of Dextran to Rhesus macaques (Macaca mulatta)","volume":"68","author":"Dufour","year":"2018","journal-title":"Comp. Med."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0130","author":"Biogen"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/mds.28359","article-title":"Hydrocephalus complicating intrathecal antisense oligonucleotide therapy for Huntington\u2019s disease","volume":"36","author":"Stoker","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0140","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"Thorne","year":"2004","journal-title":"Neuroscience."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0145","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/mt.2011.291","article-title":"Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the Postischemic brain","volume":"20","author":"Kim","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0150","first-page":"418","article-title":"Gene delivery into the central nervous system by nasal instillation in rats","volume":"2","author":"Draghia","year":"1995","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/rej.2010.1130","article-title":"Therapeutic efficacy of Intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease","volume":"14","author":"Danielyan","year":"2011","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0160","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s12035-018-1109-6","article-title":"Intranasal delivery of pGDNF DNA nanoparticles provides neuroprotection in the rat 6-Hydroxydopamine model of Parkinson\u2019s disease","volume":"56","author":"Aly","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2019.102119","article-title":"Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington\u2019s disease gene expression following intranasal administration","volume":"24","author":"Sava","year":"2020","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0175","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biopsych.2009.09.020","article-title":"Intranasal oxytocin improves emotion recognition for youth with autism Spectrum disorders","volume":"67","author":"Guastella","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0180","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0185","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/jcbfm.2014.215","article-title":"Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration","volume":"35","author":"Lochhead","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0190","first-page":"20","article-title":"Intranasal delivery of hGDNF plasmid DNA nanoparticles results in long-term and widespread transfection of perivascular cells in rat brain, nanomedicine Nanotechnol","volume":"16","author":"Aly","year":"2019","journal-title":"Biol. Med."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0195","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/jps.21939","article-title":"Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations","volume":"99","author":"Migliore","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0200","doi-asserted-by":"crossref","first-page":"20418","DOI":"10.1074\/jbc.M602077200","article-title":"Apolipoprotein A-I assumes a \u201cLooped Belt\u201d conformation on reconstituted high density lipoprotein*","volume":"281","author":"Martin","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0205","doi-asserted-by":"crossref","first-page":"8600","DOI":"10.1021\/bi050421z","article-title":"A mass spectrometric determination of the conformation of dimeric apolipoprotein A-I in discoidal high density lipoproteins","volume":"44","author":"Silva","year":"2005","journal-title":"Biochemistry."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/nn103098m","article-title":"Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures","volume":"5","author":"Bricarello","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0215","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2010.07.057","article-title":"A phospholipid\u2013apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties","volume":"399","author":"Burgess","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0220","first-page":"162","article-title":"Curcumin nanodisks: formulation and characterization, nanomedicine Nanotechnol","volume":"7","author":"Ghosh","year":"2011","journal-title":"Biol. Med."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0225","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2010.08209.x","article-title":"All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma","volume":"150","author":"Singh","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0230","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s11095-012-0957-4","article-title":"Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA","volume":"30","author":"Rui","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0235","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001156","article-title":"Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus","volume":"3","author":"Stukas","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0240","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1194\/jlr.M085332","article-title":"A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL","volume":"59","author":"Cooke","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0245","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1046-5928(02)00568-5","article-title":"Optimized bacterial expression of human apolipoprotein A-I","volume":"27","author":"Ryan","year":"2003","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0250","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1021\/bi001922h","article-title":"Cysteine substitutions in apolipoprotein A-I primary structure modulate Paraoxonase activity","volume":"40","author":"Oda","year":"2001","journal-title":"Biochemistry."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0255","doi-asserted-by":"crossref","first-page":"12166","DOI":"10.1038\/srep12166","article-title":"Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression","volume":"5","author":"Southwell","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0260","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable Polyglutamine repeat can elicit progressive and selective Neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0265","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/JHD-200463","article-title":"Reliable resolution of full-length huntingtin alleles by quantitative immunoblotting","volume":"10","author":"Caron","year":"2021","journal-title":"J. Huntingt. Dis."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0270","doi-asserted-by":"crossref","first-page":"12291","DOI":"10.1073\/pnas.94.23.12291","article-title":"Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation","volume":"94","author":"Borhani","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0275","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-2275(20)41536-6","article-title":"The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function","volume":"33","author":"Segrest","year":"1992","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0280","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0006-3495(92)81698-3","article-title":"Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism","volume":"63","author":"Nolte","year":"1992","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0285","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.nbd.2011.09.003","article-title":"Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease","volume":"45","author":"Franciosi","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0290","doi-asserted-by":"crossref","first-page":"41316","DOI":"10.1038\/srep41316","article-title":"Impairment of blood-brain barrier is an early event in R6\/2 mouse model of Huntington disease","volume":"7","author":"Di Pardo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0295","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.24406","article-title":"Cerebrovascular and blood\u2013brain barrier impairments in Huntington\u2019s disease: potential implications for its pathophysiology","volume":"78","author":"Drouin-Ouellet","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0300","series-title":"The Molecular Interaction of Apolipoprotein A-I and Lecithin: Cholesterol Acyl Transferase","author":"Cooke","year":"2018"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0305","doi-asserted-by":"crossref","first-page":"9356","DOI":"10.3390\/ijms23169356","article-title":"HDL-like-mediated cell cholesterol trafficking in the central nervous system and Alzheimer\u2019s disease pathogenesis","volume":"23","author":"Borr\u00e0s","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0310","first-page":"117","article-title":"A novel role for scavenger receptor B1 as a contributor to the capture of specific volatile odorants in the nasal cavity","volume":"39","author":"Tsuzuki","year":"2018","journal-title":"Biomed. Res. Tokyo Jpn."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0315","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-2275(20)31693-X","article-title":"Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI","volume":"42","author":"de Beer","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0320","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/pharmaceutics11110598","article-title":"Perivascular and Perineural pathways involved in brain delivery and distribution of drugs after intranasal administration","volume":"11","author":"Lochhead","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0325","doi-asserted-by":"crossref","unstructured":"B. Highet, B.V. Dieriks, H.C. Murray, R.L.M. Faull, M.A. Curtis, Huntingtin aggregates in the olfactory bulb in Huntington's disease, Front. Aging Neurosci. 12 (2020). doi:https:\/\/doi.org\/10.3389\/fnagi.2020.00261 (accessed September 9, 2022).","DOI":"10.3389\/fnagi.2020.00261"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0330","doi-asserted-by":"crossref","unstructured":"J. Patino, N.E. Karagas, S. Chandra, N. Thakur, E.F. Stimming, Olfactory dysfunction in Huntington's disease, J. Huntingt. Dis. 10 (n.d.) 413\u2013422. doi:https:\/\/doi.org\/10.3233\/JHD-210497.","DOI":"10.3233\/JHD-210497"},{"key":"10.1016\/j.jconrel.2023.07.027_bb0335","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1021\/acs.bioconjchem.8b00548","article-title":"Passive immunotherapies for central nervous system disorders \u2013 current delivery challenges and new approaches","volume":"29","author":"Kumar","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0340","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/toxsci\/kfg075","article-title":"The effect of lung structure on mucociliary clearance and particle retention in human and rat lungs","volume":"73","author":"Hofmann","year":"2003","journal-title":"Toxicol. Sci. Off. J. Soc. Toxicol."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102944","article-title":"Anti-\u03b1-synuclein ASO delivered to monoamine neurons prevents \u03b1-synuclein accumulation in a Parkinson\u2019s disease-like mouse model and in monkeys","volume":"59","author":"Alarc\u00f3n-Ar\u00eds","year":"2020","journal-title":"EBioMedicine."},{"key":"10.1016\/j.jconrel.2023.07.027_bb0350","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","article-title":"Selective \u03b1-Synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson\u2019s disease","volume":"26","author":"Alarc\u00f3n-Ar\u00eds","year":"2018","journal-title":"Mol. Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923004510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923004510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:55:24Z","timestamp":1759164924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923004510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":70,"alternative-id":["S0168365923004510"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.027","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}